Vertex Pharma (VRTX) Tops Q4 EPS by 8c, Offers Guidance
Get Alerts VRTX Hot Sheet
Price: $397.70 -0.76%
Revenue Growth %: +8.9%
Financial Fact:
Provision for income taxes (Alios): 503K
Today's EPS Names:
FRSB, DGICA, UXIN, More
Revenue Growth %: +8.9%
Financial Fact:
Provision for income taxes (Alios): 503K
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $3.37, $0.08 better than the analyst estimate of $3.29. Revenue for the quarter came in at $2.07 billion versus the consensus estimate of $2 billion.
GUIDANCE:
Vertex Pharma sees FY2022 revenue of $8.4-8.6 billion, versus the consensus of $8.22 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Byline Bancorp (BY) Tops Q1 EPS by 6c
- Northeast Community Bancorp, Inc. (NECB) Tops Q1 EPS by 12c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!